Kang Stem Biotech receives final clinical report for 'Oscar' trial, says 'consistency of key results confirmed'
Predicted impact: Low
Final clinical trial report receipt; results described only as consistent, with no size given.
Kangstem Biotech강스템바이오텍
217730 · KOSDAQ · ₩217730 · 강스템바이오텍
₩1,863▼ ₩2 (0.11%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y +29.38%
- Market cap
- ₩175B
- Enterprise value
- ₩155B
- P/E
- —
- P/B
- 3.1×
- Dividend yield
- 0.0%
- ROE
- −20.5%
- Net margin
- −381.3%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−60.3% from the high
₩1,376Today: ₩1,853 – ₩1,919₩4,690
Returns
- 1W−5.2%
- 1M−12.5%
- 3M−6.6%
- 6M−53.9%
- YTD−19.7%
- 1Y+29.4%
- Volume today
- 207,135
- 0.8× the 20-day average
- Traded today
- ₩387M
- Listed shares
- 94,054,149
- EPS (12 months)
- −₩123
- Earnings yield −6.6%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 39 of 100 (50 is a normal day for this stock).
- SentimentMixedNews: The trial report is positive, but the management filing has no details, so the overall tone is neutral. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-9.6% over the last month; the price is below its 20-day average.
- News impactSome2 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
Kangstem Biotech stock overview
Kangstem Biotech (강스템바이오텍, KRX: 217730) is listed on KOSDAQ, in the Biotech & Pharma sector. The company, founded in 2010, develops and manufactures stem cell therapies and operates two main business units: stem cell and cosmetics. Its shares closed at ₩1,863 on Oct 28, 2026, down 0.11% on the day, giving it a market value of ₩175B.
Key facts
- Market cap
- ₩175B
- Sector
- Biotech & Pharma
- Latest price change
- −0.11%
- As of
- Oct 28, 2026
- Main business
- The company, founded in 2010, develops and manufactures stem cell therapies and operates two main business units: stem cell and cosmetics.
Quick answers about Kangstem Biotech
- What does Kangstem Biotech do?
- The company, founded in 2010, develops and manufactures stem cell therapies and operates two main business units: stem cell and cosmetics. Its stem cell business uses proprietary multipotent stem cells isolated from human umbilical cord blood, with pipeline products for atopic dermatitis, rheumatoid arthritis, and osteoarthritis. Its cosmetics business sells products based mainly on its stem cell culture medium, primarily through online distribution channels.
- What is the market cap of Kangstem Biotech?
- The market capitalisation of Kangstem Biotech was ₩175B at the close on Oct 28, 2026.
- Who are the largest shareholders of Kangstem Biotech?
- According to the latest official filings, the largest reported holders are Sejong (19.79%, as of Aug 26, 2025); Kang Gyeong-seon (5.31%, as of Apr 3, 2026); Choi Jeong-ho (0.28%, as of Aug 28, 2025).
- When is the next earnings report from Kangstem Biotech?
- Korean companies rarely announce results dates in advance. Based on when Kangstem Biotech filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own Kangstem Biotech?
- Yes. The National Pension Service held 0.10% of Kangstem Biotech shares as of Dec 31, 2019.
Company profile
The company, founded in 2010, develops and manufactures stem cell therapies and operates two main business units: stem cell and cosmetics. Its stem cell business uses proprietary multipotent stem cells isolated from human umbilical cord blood, with pipeline products for atopic dermatitis, rheumatoid arthritis, and osteoarthritis. Its cosmetics business sells products based mainly on its stem cell culture medium, primarily through online distribution channels.
Written by AI from the company's latest annual report.
- Korean name
- 강스템바이오텍
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 나종천
- Founded
- Oct 2010
- Listed
- Dec 2015
- Listed shares
- 94,054,149
- Fiscal year ends
- Month 12
- Website
- www.kangstem.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent news
Recent filings
See all- Major management matter relevant to investorsOct 26, 2026
- Investor relations (IR) eventSep 30, 2026
- Half-year report (Jun 2026)Aug 13, 2026
- Investor relations (IR) eventJul 28, 2026
- Major management matter relevant to investorsJul 28, 2026
Titles in Korean until English translations are added.
Also known as: Kangstem Biotech / 강스템바이오텍 / 217730 / KRX:217730
Source: KRX statistical information